The five-year agreement provides Celling with an initial two year period of exclusive distribution rights in the US and non-exclusive distribution rights throughout the rest of the world, excluding Central and South America, Russia and certain Eastern European countries. ThermoGenesis will establish distributor relationships in those geographies.
The distribution rights are for the field of use in orthopedic intraoperative or point-of-care applications. Celling Technologies will begin using the MarrowXpress (MXP) to perform bone marrow stem cell separation for its existing point-of-care orthopedic procedures and perform clinical research utilizing this unique technology.
William Osgood, CEO of ThermoGenesis, said: “We are delighted to be partnering with Celling Technologies. Their business model, which incorporates a high level of on-site service to clinicians, was a very important factor in our decision to establish our relationship.”